バイオシミラーの世界市場予測(~2023年):製品、製造タイプ、疾患、地域別分析

◆英語タイトル:Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023
◆発行会社/調査会社:MarketsandMarkets
◆商品コード:MAM-BT-2160
◆発行日:2018年4月6日
◆調査対象地域:グローバル
◆産業分野:バイオ
◆ページ数:183
◆レポート言語:
◆レポート形式:PDF
◆納品方式:Eメール(受注後24時間以内)
◆販売価格オプション(消費税別)
Single User(1名利用)USD5,650 ⇒換算¥632,800見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥744,800見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥912,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
MarketsandMarkets社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[バイオシミラーの世界市場予測(~2023年):製品、製造タイプ、疾患、地域別分析]についてメールでお問い合わせはこちら
MarketsandMarketsが発行した当調査レポートでは、バイオシミラーの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、製品別分析、製造タイプ別分析、疾患別分析、地域別分析、バイオシミラーの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。
*** レポート概要(サマリー)***

“The global biosimilars market projected to grow at a CAGR of 31.7% during the forecast period.”The biosimilars market is expected to reach USD 23.63 billion by 2023 from USD 5.95 billion in 2018, at a CAGR of 31.7%. Factors driving the growth of this market include increasing demand for biosimilar drugs due to their cost-effectiveness, rising incidence of chronic diseases, and strategic collaborations resulting in enhanced productivity and clinical trial activities.
“The recombinant glycosylated protein segment is anticipated to grow at the fastest growth rate during the forecast period.”
The biosimilars market by product is categorized into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant glycosylated proteins segment is expected to register the highest CAGR during the forecast period. The factors driving the market for glycosylated proteins are the broad therapeutic area of these proteins; presence of biosimilar versions of monoclonal antibodies at lower prices compared to reference products; numerous biologic drugs underclass monoclonal antibody, follitropin, and erythropoietin going off-patent; and numerous products in the pipeline.
“The contract manufacturing segment is estimated to grow at a rapid rate during the analysis period.”
By type of manufacturing, the biosimilars market is segmented into in-house manufacturing and contract manufacturing. The contract manufacturing segment is expected to grow at the highest CAGR during the forecast period. CMOs provide cost-saving benefits to companies in terms of facilities, equipment, and labor costs.
“Asia is estimated to register the highest CAGR during the study period.”
On the basis of region, the biosimilars market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR during the forecast period. Many Asian countries such as India, China, South Korea, and Japan have emerged as potential markets for biosimilars. Many emerging economies in the region are also establishing biosimilar pathways. Moreover, leading market players are outsourcing manufacturing and R&D activities to countries in the Asia Pacific region due to the availability of highly skilled resources at lower costs. In addition to this, the low per capita consumption, rapid growth in economies, trade links, and the rise in medical tourism are accelerating the growth of the Asian market.
The primary interviews conducted for this report can be categorized as follows:
• By Company Type – Tier 1 – 70% and Tier 2 – 30%
• By Designation – C-level – 62%, Director-level – 21%, Others – 17%
• By Region – North America – 50%, Europe – 20%, Asia– 30%

The key players in the biosimilars market include Pfizer (US), Sandoz (Germany), Teva Pharmaceuticals (Israel), Amgen (US), Biocon (India), Dr. Reddy’s Laboratories (India), Celltrion (South Korea), and Samsung Biologics
Research Coverage:
The report analyses the biosimilars market by products, type of manufacturing, disease, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.
Key benefits of buying the Report:
This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms, garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.
The report provides insights on the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the biosimilars market
• Product Development/Innovation: Detailed insights on product approvals, R&D activities, and product launches in the biosimilars market
• Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the biosimilars market
• Market Development: Comprehensive information about emerging markets. This report analyzes the market for various biosimilars across geographies
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market

*** レポート目次(コンテンツ)***

TABLE OF CONTENTS

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 17
1.3.1 MARKET COVERED 17
1.4 YEARS CONSIDERED FOR THE STUDY 18
1.5 CURRENCY 18
1.6 LIMITATIONS 18
1.7 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 SECONDARY DATA 20
2.1.1 SECONDARY SOURCES 20
2.2 PRIMARY DATA 21
2.2.1 PRIMARY SOURCES 22
2.3 MARKET SIZE ESTIMATION 22
2.3.1 BOTTOM-UP APPROACH 23
2.3.2 TOP-DOWN APPROACH 24
2.4 DATA TRIANGULATION METHODOLOGY 25
2.5 ASSUMPTIONS FOR THE STUDY 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 30
4.1 BIOSIMILARS MARKET OVERVIEW 30
4.2 ASIA: BIOSIMILARS MARKET, BY TYPE OF PRODUCT 31
4.3 BIOSIMILARS MARKET, BY REGION 32
4.4 GEOGRAPHICAL SNAPSHOT: BIOSIMILARS MARKET (MAJOR COUNTRIES) 33
5 MARKET OVERVIEW 34
5.1 INTRODUCTION 34
5.2 MARKET DYNAMICS 34
5.2.1 DRIVERS 35
5.2.1.1 Increasing demand for biosimilar drugs due to their cost-effectiveness 35
5.2.1.2 Rising incidence of chronic diseases 35
5.2.1.3 Strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars 36

5.2.2 RESTRAINTS 37
5.2.2.1 Complexities in manufacturing 37
5.2.2.2 Innovative strategies by biologic drug manufacturers 37
5.2.3 OPPORTUNITIES 38
5.2.3.1 Growth opportunities in emerging markets 38
5.2.3.2 New indications and patent expiry of biologic products 38
5.2.4 CHALLENGES 40
5.2.4.1 Stringent regulatory requirements to adversely affect investments in biosimilars 40
6 REGULATORY OUTLOOK 41
6.1 NORTH AMERICA 41
6.1.1 US 41
6.1.2 CANADA 41
6.2 EUROPE 42
6.3 ASIA PACIFIC 43
6.3.1 CHINA 43
6.3.2 INDIA 43
6.3.3 JAPAN 43
6.3.4 SOUTH KOREA 43
6.4 REST OF THE WORLD 44
6.4.1 BRAZIL 44
6.4.2 MEXICO 44
6.4.3 ARGENTINA 44
6.4.4 SAUDI ARABIA 44
7 BIOSIMILARS MARKET, BY PRODUCT 45
7.1 INTRODUCTION 46
7.2 RECOMBINANT NON-GLYCOSYLATED PROTEINS 47
7.2.1 RECOMBINANT HUMAN GROWTH HORMONE (RHGH) 48
7.2.2 GRANULOCYTE COLONY-STIMULATING FACTOR (FILGRASTIM) 49
7.2.3 INSULIN 51
7.2.4 INTERFERONS 52
7.2.4.1 Interferon-beta 53
7.2.4.2 Interferon-alpha 53
7.3 RECOMBINANT GLYCOSYLATED PROTEINS 54
7.3.1 ERYTHROPOIETIN (EPO) 55
7.3.2 MONOCLONAL ANTIBODIES (MABS) 56
7.3.2.1 Infliximab 57
7.3.2.2 Rituximab 58
7.3.2.3 Adalimumab 59
7.3.2.4 Other monoclonal antibodies 61

7.3.3 FOLLITROPIN 62
7.4 RECOMBINANT PEPTIDES 62
7.4.1 GLUCAGON 64
7.4.2 CALCITONIN 64
8 BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING 66
8.1 INTRODUCTION 67
8.2 IN-HOUSE MANUFACTURING 68
8.3 CONTRACT MANUFACTURING 68
9 BIOSIMILARS MARKET, BY DISEASE 70
9.1 INTRODUCTION 71
9.2 ONCOLOGY 72
9.3 CHRONIC DISEASES 73
9.4 AUTOIMMUNE DISEASES 74
9.5 BLOOD DISORDERS 75
9.6 GROWTH HORMONE DEFICIENCY 76
9.7 INFECTIOUS DISEASES 77
9.8 OTHER DISEASES 78
10 BIOSIMILARS MARKET, BY REGION 79
10.1 INTRODUCTION 80
10.2 NORTH AMERICA 81
10.2.1 US 85
10.2.2 CANADA 88
10.3 EUROPE 92
10.3.1 GERMANY 98
10.3.2 FRANCE 100
10.3.3 UK 102
10.3.4 ITALY 104
10.3.5 SPAIN 106
10.3.6 REST OF EUROPE 108
10.4 ASIA 111
10.4.1 INDIA 116
10.4.2 CHINA 121
10.4.3 SOUTH KOREA 124
10.4.4 JAPAN 128
10.4.5 REST OF ASIA 131
10.5 REST OF THE WORLD (ROW) 135
10.5.1 LATIN AMERICA 139
10.5.2 PACIFIC AND OCEANIA 140
10.5.3 MIDDLE EAST AND AFRICA 141
11 COMPETITIVE LANDSCAPE 143
11.1 OVERVIEW 143
11.2 MARKET SHARE ANALYSIS, 2016 144
11.3 COMPETITIVE SCENARIO 145
11.3.1 PRODUCT LAUNCHES AND PRODUCT APPROVALS 145
11.3.2 PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS 146
11.3.3 ACQUISITIONS 146
11.3.4 EXPANSIONS 147
12 COMPANY PROFILES 148
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
12.1 SANDOZ 148
12.2 PFIZER 151
12.3 TEVA PAHRMACEUTICAL 154
12.4 CELLTRION 156
12.5 BIOCON 158
12.6 AMGEN 160
12.7 SAMSUNG BIOLOGICS 162
12.8 MYLAN 164
12.9 DR. REDDY’S LABORATORIES 166
12.10 STADA ARZNEIMITTEL AG 168

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
13 APPENDIX 170
13.1 INSIGHTS OF INDUSTRY EXPERTS 170
13.2 DISCUSSION GUIDE 171
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 175
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 177
13.5 AVAILABLE CUSTOMIZATIONS 179
13.6 RELATED REPORTS 180
13.7 AUTHOR DETAILS 181

LIST OF TABLES

TABLE 1 MAJOR COLLABORATIONS IN THE BIOSIMILARS MARKET (2015–2018) 36
TABLE 2 LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY 39
TABLE 3 STATUS OF REGULATORY PATHWAY IN NORTH AMERICA 41
TABLE 4 SUBSTITUTION STATUS IN EUROPEAN COUNTRIES 42
TABLE 5 STATUS OF REGULATORY PATHWAY IN ASIA PACIFIC 43
TABLE 6 STATUS OF REGULATORY PATHWAY IN THE ROW 44
TABLE 7 BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 46
TABLE 8 BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 47
TABLE 9 BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS,
BY REGION, 2016–2023 (USD MILLION) 48
TABLE 10 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE,
BY REGION, 2016–2023 (USD MILLION) 49
TABLE 11 LIST OF APPROVED BIOSIMILARS FOR GRANULOCYTE COLONY-STIMULATING FACTOR PRODUCTS FROM 2013 TO 2016 50
TABLE 12 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR,
BY REGION, 2016–2023 (USD MILLION) 50
TABLE 13 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2016–2023 (USD MILLION) 51
TABLE 14 BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE, 2016–2023 (USD MILLION) 52
TABLE 15 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION,
2016–2023 (USD MILLION) 52
TABLE 16 BIOSIMILARS MARKET FOR INTERFERON-BETA , BY REGION,
2016–2023 (USD MILLION) 53
TABLE 17 BIOSIMILARS MARKET FOR INTERFERON-ALPHA, BY REGION,
2016–2023 (USD MILLION) 54
TABLE 18 BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD BILLION) 55
TABLE 19 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN 56
TABLE 20 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION,
2016–2023 (USD MILLION) 56
TABLE 21 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD BILLION) 57
TABLE 22 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY REGION, 2016–2023 (USD MILLION) 57
TABLE 23 PIPELINE OF INFLXIMAB 58
TABLE 24 BIOSIMILARS MARKET FOR INFLXIMAB, BY REGION, 2016–2023 (USD MILLION) 58
TABLE 25 PIPELINE OF RITUXIMAB 59
TABLE 26 BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2016–2023 (USD MILLION) 59
TABLE 27 PIPELINE OF ADLIMUMAB 60
TABLE 28 BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2016–2023 (USD MILLION) 60
TABLE 29 PIPELINE OF OTHER MONOCLONAL ANTIBODIES 61
TABLE 30 BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION,
2016–2023 (USD MILLION) 61
TABLE 31 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2016–2023 (USD MILLION) 62
TABLE 32 BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE,
2016–2023 (USD MILLION) 63
TABLE 33 BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY REGION,
2016–2023 (USD MILLION) 63
TABLE 34 BIOSIMILARS MARKET FOR GLUCAGON, BY REGION, 2016–2023 (USD MILLION) 64
TABLE 35 BIOSIMILARS MARKET FOR CALCITONIN, BY REGION, 2016–2023 (USD MILLION) 65
TABLE 36 BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016–2023 (USD MILLION) 67
TABLE 37 BIOSIMILARS MARKET FOR IN-HOUSE MANUFACTURING, BY REGION,
2016–2023 (USD BILLION) 68
TABLE 38 BIOSIMILARS MARKET FOR CONTRACT MANUFACTURING, BY REGION,
2016–2023 (USD MILLION) 69
TABLE 39 BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 71
TABLE 40 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2016–2023 (USD MILLION) 72
TABLE 41 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION,
2016–2023 (USD MILLION) 73
TABLE 42 BIOSIMILARS MARKET FOR AUTOIMMUNE DISEASES, BY REGION,
2016–2023 (USD MILLION) 74
TABLE 43 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION,
2016–2023 (USD MILLION) 75
TABLE 44 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY,
BY REGION, 2016–2023 (USD MILLION) 76
TABLE 45 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION,
2016–2023 (USD MILLION) 77
TABLE 46 BIOSIMILARS MARKET FOR OTHER DISEASES, BY REGION,
2016–2023 (USD MILLION) 78
TABLE 47 BIOSIMILARS MARKET, BY REGION, 2016–2023 (USD MILLION) 80
TABLE 48 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 82
TABLE 49 NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 82
TABLE 50 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 82
TABLE 51 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 83
TABLE 52 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 83
TABLE 53 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 84
TABLE 54 NORTH AMERICA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 84
TABLE 55 NORTH AMERICA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 84
TABLE 56 LIST OF BIOSIMILARS APPROVED IN THE US 85
TABLE 57 US: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 86
TABLE 58 US: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 86
TABLE 59 US: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 86
TABLE 60 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE,
2016–2023 (USD MILLION) 87
TABLE 61 US: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 87
TABLE 62 US: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 88
TABLE 63 LIST OF BIOSIMILARS APPROVED IN CANADA 89
TABLE 64 CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 89
TABLE 65 CANADA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 89
TABLE 66 CANADA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 90
TABLE 67 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 90
TABLE 68 CANADA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 91
TABLE 69 CANADA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 91
TABLE 70 CANADA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 91
TABLE 71 LIST OF BIOSIMILARS APPROVED IN EUROPE 92
TABLE 72 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 95
TABLE 73 EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 95
TABLE 74 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 96
TABLE 75 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 96
TABLE 76 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE,
2016–2023 (USD MILLION) 96
TABLE 77 EUROPE: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 97
TABLE 78 EUROPE: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 97
TABLE 79 GERMANY: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 98
TABLE 80 GERMANY: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 98
TABLE 81 GERMANY: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 99
TABLE 82 GERMANY: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 99
TABLE 83 GERMANY: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 99
TABLE 84 FRANCE: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 100
TABLE 85 FRANCE: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 100
TABLE 86 FRANCE: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 101
TABLE 87 FRANCE: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 101
TABLE 88 FRANCE: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 101
TABLE 89 LIST OF BIOSIMILARS IN THE UK 102
TABLE 90 UK: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 102
TABLE 91 UK: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 103
TABLE 92 UK: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 103
TABLE 93 UK: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 103
TABLE 94 UK: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 104
TABLE 95 ITALY: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 104
TABLE 96 ITALY: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 105
TABLE 97 ITALY: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 105
TABLE 98 ITALY: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 105
TABLE 99 ITALY: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 106
TABLE 100 SPAIN: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 106
TABLE 101 SPAIN: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 107
TABLE 102 SPAIN: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 107
TABLE 103 SPAIN: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 107
TABLE 104 SPAIN: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 108
TABLE 105 ROE: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 109
TABLE 106 ROE: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 109
TABLE 107 ROE: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 109
TABLE 108 ROE: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 110
TABLE 109 ROE: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 110
TABLE 110 ASIA: BIOSIMILARS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 113
TABLE 111 ASIA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 113
TABLE 112 ASIA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 113
TABLE 113 ASIA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE,
2016–2023 (USD MILLION) 114
TABLE 114 ASIA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 114
TABLE 115 ASIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 114
TABLE 116 ASIA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 115
TABLE 117 ASIA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 115
TABLE 118 ASIA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 115
TABLE 119 BIOLOGICS APPROVED AND MARKETED IN INDIA 116
TABLE 120 INDIA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 118
TABLE 121 INDIA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 119
TABLE 122 INDIA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE,
2016–2023 (USD MILLION) 119
TABLE 123 INDIA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 119
TABLE 124 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 120
TABLE 125 INDIA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 120
TABLE 126 INDIA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 120
TABLE 127 INDIA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 121
TABLE 128 CHINA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 122
TABLE 129 CHINA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 122
TABLE 130 CHINA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE,
2016–2023 (USD MILLION) 122
TABLE 131 CHINA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 123
TABLE 132 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 123
TABLE 133 CHINA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 123
TABLE 134 CHINA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 124
TABLE 135 CHINA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 124
TABLE 136 LIST OF BIOSIMILARS APPROVED IN SOUTH KOREA 125
TABLE 137 SOUTH KOREA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 125
TABLE 138 SOUTH KOREA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 126
TABLE 139 SOUTH KOREA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 126
TABLE 140 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 127
TABLE 141 SOUTH KOREA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 127
TABLE 142 SOUTH KOREA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 127
TABLE 143 LIST OF BIOSIMILARS APPROVED IN JAPAN 128
TABLE 144 JAPAN: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 129
TABLE 145 JAPAN: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 129
TABLE 146 JAPAN: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 129
TABLE 147 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 130
TABLE 148 JAPAN: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 130
TABLE 149 JAPAN: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 130
TABLE 150 JAPAN: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 131
TABLE 151 ROA: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 132
TABLE 152 ROA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 132
TABLE 153 ROA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE,
2016–2023 (USD MILLION) 132
TABLE 154 ROA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 133
TABLE 155 ROA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES,
BY TYPE, 2016–2023 (USD MILLION) 133
TABLE 156 ROA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES,
BY TYPE, 2016–2023 (USD MILLION) 133
TABLE 157 ROA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 134
TABLE 158 ROA: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 134
TABLE 159 ROW: BIOSIMILARS MARKET, BY REGION, 2016–2023 (USD MILLION) 137
TABLE 160 ROW: BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 137
TABLE 161 ROW: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016–2023 (USD MILLION) 137
TABLE 162 ROW: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS,
BY TYPE, 2016–2023 (USD MILLION) 138
TABLE 163 ROW: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE,
2016–2023 (USD MILLION) 138
TABLE 164 ROW: BIOSIMILARS MARKET, BY MANUFACTURING TYPE,
2016–2023 (USD MILLION) 138
TABLE 165 ROW: BIOSIMILARS MARKET, BY DISEASE, 2016–2023 (USD MILLION) 139
TABLE 166 LIST OF SIMILAR BIOTHERAPEUTIC PRODUCTS APPROVED IN LATIN AMERICA 139
TABLE 167 LATIN AMERICA : BIOSIMILARS MARKET, BY PRODUCT, 2016–2023 (USD MILLION) 140
TABLE 168 LIST OF BIOSIMILARS APPROVED IN AUSTRALIA 140
TABLE 169 LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND 141
TABLE 170 PACIFIC AND OCEANIA: BIOSIMILARS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 141
TABLE 171 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY PRODUCT,
2016–2023 (USD MILLION) 142
TABLE 172 THE COMPANY’S BIOSIMILAR IN PIPELINE ARE LISTED BELOW 152
TABLE 173 THE COMPANY’S BIOSIMILAR IN PIPELINE ARE LISTED BELOW 155
TABLE 174 THE COMPANY’S BIOSIMILAR IN PIPELINE ARE LISTED BELOW 157
TABLE 175 THE COMPANY’S BIOSIMILAR IN PIPELINE ARE LISTED BELOW 161
TABLE 176 THE COMPANY’S BIOSIMILAR IN PIPELINE ARE LISTED BELOW 162


LIST OF FIGURES

FIGURE 1 RESEARCH METHODOLOGY 19
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS 21
FIGURE 3 BOTTOM-UP APPROACH 23
FIGURE 4 TOP-DOWN APPROACH 24
FIGURE 5 DATA TRIANGULATION 25
FIGURE 6 BIOSIMILARS MARKET, BY PRODUCT, 2018 VS. 2023 (USD MILLION) 27
FIGURE 7 BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2018 VS. 2023 (USD MILLION) 28
FIGURE 8 BIOSIMILARS MARKET, BY DISEASE, 2018 VS. 2023 (USD MILLION) 28
FIGURE 9 BIOSIMILARS MARKET, BY REGION, 2018 VS. 2023 (USD BILLION) 29
FIGURE 10 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE MARKET 30
FIGURE 11 RECOMBINANT GLYCOSYLATED PROTIENS SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017 31
FIGURE 12 NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE IN 2017 32
FIGURE 13 INDIA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 33
FIGURE 14 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES 34
FIGURE 15 INCREASING GERIATRIC POPULATION, BY REGION, 2015 VS. 2030 35
FIGURE 16 GLOBAL INCIDENCE OF DIABETES, BY REGION, 2017 VS. 2045 36
FIGURE 17 BIOSIMILARS MARKET, BY PRODUCT, 2018 VS. 2023 (USD MILLION) 46
FIGURE 18 IN-HOUSE MANUFACTURING SEGMENT TO DOMINATE THE BIOSIMILARS MARKET IN 2018 67
FIGURE 19 ONCOLOGY SEGMENT TO DOMINATE THE BIOSIMILARS MARKET IN 2018 71
FIGURE 20 ASIA TO REGISTER THE HIGHEST GROWTH RATE IN THE BIOSIMILARS MARKET DURING THE FORECAST PERIOD 80
FIGURE 21 NORTH AMERICA: BIOSIMILARS MARKET SNAPSHOT 81
FIGURE 22 CANCER INCIDENCE IN CANADA 88
FIGURE 23 EUROPE: BIOSIMILARS MARKET SNAPSHOT 94
FIGURE 24 ASIA: BIOSIMILARS MARKET SNAPSHOT 112
FIGURE 25 ROW: BIOSIMILARS MARKET SNAPSHOT 136
FIGURE 26 KEY DEVELOPMENTS OF MAJOR PLAYERS FROM 2015 TO 2018 143
FIGURE 27 GLOBAL BIOSIMILARS MARKET SHARE ANALYSIS, BY KEY PLAYER 2016 144
FIGURE 28 SANDOZ: COMPANY SNAPSHOT 148
FIGURE 29 PFIZER: COMPANY SNAPSHOT 151
FIGURE 30 TEVA PHARMACEUTICAL: COMPANY SNAPSHOT 154
FIGURE 31 CELLTRION: COMPANY SNAPSHOT 156
FIGURE 32 BIOCON: COMPANY SNAPSHOT 158
FIGURE 33 AMGEN: COMPANY SNAPSHOT 160
FIGURE 34 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT 162
FIGURE 35 MYLAN: COMPANY SNAPSHOT 164
FIGURE 36 DR. REDDY'S LABORATORIES: COMPANY SNAPSHOT 166
FIGURE 37 STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT 168


*** レポートのキーワード ***

バイオシミラー、バイオ後続品、医薬品

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(MAM-BT-2160 )"バイオシミラーの世界市場予測(~2023年):製品、製造タイプ、疾患、地域別分析" (英文:Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing Type (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023)はMarketsandMarkets社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。